Renzapride

Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist[1]. Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study[2].

Product Specifications

CAS Number

[112727-80-7]

Product Name Alternative

BRL 24924

UNSPSC

12352005

Target

5-HT Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/renzapride.html

Purity

98.36

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

ClC1=C(N)C=C(OC)C(C(N[C@H]2CCN3CCC[C@@H]2C3)=O)=C1

Molecular Formula

C16H22ClN3O2

Molecular Weight

323.82

References & Citations

[1]Camilleri M, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004;2 (10) :895-904.|[2]Scarpellini E, et al. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs. 2008;17 (11) :1663-1670.|[3]Nagakura Y, et al. Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor. Pharmacol Res. 1999;39 (5) :375-382.|[4]Mawe GM, et al. Blockade of 5-HT-mediated enteric slow EPSPs by BRL 24924: gastrokinetic effects. Am J Physiol. 1989;257 (3 Pt 1) :G386-G396.